TLDR Baricitinib may not always prevent relapse in alopecia areata.
Alopecia areata (AA) is a difficult condition to treat, traditionally managed with corticosteroids and immunosuppressants. The FDA's approval of baricitinib, a Janus kinase inhibitor (JAKi), was a major advancement, showing promising results in clinical trials. However, this article discusses a rare case of a 30-year-old male with severe patch-type AA who, despite initially responding well to baricitinib, experienced a relapse while still on the treatment. This case highlights the challenges and potential limitations of baricitinib therapy in AA management.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
40 citations
,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
30 citations
,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.
